Get the Stockscreener App
11.90
2.38%
-0.29
Kalvista Pharmaceuticals Inc stock is traded at $11.90, with a volume of 377.25K.
It is down -2.38% in the last 24 hours and up +9.98% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
See More
Previous Close:
$12.19
Open:
$12.2
24h Volume:
377.25K
Relative Volume:
0.66
Market Cap:
$673.65M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-3.2249
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
-12.18%
1M Performance:
+9.98%
6M Performance:
+4.29%
1Y Performance:
-1.57%
1-Day Range:
$11.88
$12.71
1-Week Range:
$11.31
$13.71
52-Week Range:
$7.30
$15.50
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare KALV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
11.90 | 673.65M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
Wells Fargo & Company MN Has $171,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
MetLife Investment Management LLC Lowers Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Transcript : KalVista Pharmaceuticals, Inc. Presents at The Citizens JMP Life Sciences Conference 2025, May-07-2025 11 - marketscreener.com
Analyzing Ratios: KalVista Pharmaceuticals Inc (KALV)’s Financial Story Unveiled - DWinneX
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
JPMorgan Chase & Co. Decreases Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Trading (KALV) With Integrated Risk Controls - news.stocktradersdaily.com
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV Stock News - GuruFocus
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 - BioSpace
Legal & General Group Plc Acquires 1,494 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Should investors be concerned about KalVista Pharmaceuticals Inc (KALV)? - uspostnews.com
KalVista Pharmaceuticals Inc [KALV] Shares Jump Approximately 27.74% Over the Year - knoxdaily.com
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference - BioSpace
KalVista Pharmaceuticals Inc (KALV) stock analysis: A comprehensive overview - uspostnews.com
Geode Capital Management LLC Sells 8,632 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Kalvista stock holds $19 target, Market Outperform rating - Investing.com
Kalvista stock holds $19 target, Market Outperform rating By Investing.com - Investing.com India
Russell Investments Group Ltd. Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts - Defense World
Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform - insights.citeline.com
(KALV) Trading Report - news.stocktradersdaily.com
Vanguard Group Inc. Acquires 104,716 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc. - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Corebridge Financial Inc. - Defense World
Wellington Management Group LLP Has $1.04 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals’ Licensing Agreement with Kaken Pharmaceutical - Global Legal Chronicle
The week in pharma: action, reaction and insight – week to April 11 - The Pharma Letter
KalVista: Poised For Rare Disease Transformation - Seeking Alpha
Kaken, Kalvista partner on HAE treatment sebetralstat in Japan - Angioedema News
KalVista licensing deal with Kaken - The Pharma Letter
KalVista Pharmaceuticals (NASDAQ:KALV) Given “Buy” Rating at Needham & Company LLC - Defense World
KalVista inks Japan licensing deal for HAE drug sebetralstat - Investing.com Australia
KalVista inks Japan licensing deal for HAE drug sebetralstat By Investing.com - Investing.com South Africa
KalVista licenses commercialisation rights for HAE to Kaken in Japan - Yahoo
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
KalVista licences HAE therapy commercialisation rights to Kaken - Pharmaceutical Technology
KalVista Pharmaceuticals Signs Agreement with Kaken Pharmaceutical - TipRanks
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - BioSpace
KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan - marketscreener.com
KalVista stock rises on licensing deal in Japan (KALV:NASDAQ) - Seeking Alpha
Kalvista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical To Commercialize Sebetralstat For HAE In Japan - MarketScreener
KalVista Pharmaceuticals, Inc. Enters into Licensing Agreement with Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - marketscreener.com
Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World
Hereditary Angioedema Pipeline: Over 20 Leading Companies - openPR.com
KalVista Strengthens Team with Strategic 87,000-Share Option Grant Package - Stock Titan
Where are the Opportunities in (KALV) - news.stocktradersdaily.com
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph
Charles Schwab Investment Management Inc. Sells 10,372 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Q4 Earnings Estimate for KALV Issued By Leerink Partnrs - Defense World
KalVista Pharmaceuticals (KALV) – Investment Analysts’ Recent Ratings Updates - Defense World
KalVista Pharmaceuticals (NASDAQ:KALV) Earns Buy Rating from Needham & Company LLC - Defense World
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):